Am 6.01.17 kam diese Q-8 Meldung, Auszug:
"Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
As previously disclosed, on December 1, 2016, a NASDAQ Hearings Panel (the “Hearings Panel”) granted a request from Osiris Therapeutics, Inc. (the “Company”) for an extension until March 10, 2017 in order to regain compliance with NASDAQ continued listing requirements with respect to its delayed Form 10-K for 2015 and its delayed Forms 10-Q for 2016."
.....nächsten Freitag...weitere Verlängerung wird es kaum geben!!